CDSCO orders crackdown on unauthorised Enclomiphene makers, sellers and retailers
India’s drug regulator has asked state drug controllers to identify and act against unapproved manufacturers, marketers, distributors and retailers of Enclomiphene products, including by suspending or cancelling permissions and stopping further sales.
What happened
retail-company · CDSCO directed state drug controllers to identify and act against unapproved manufacturers, marketers, distributors and retailers of
Key facts
- Drugs and Cosmetics Act, 1940
- New Drugs and Clinical Trials Rules, 2019
What changed
CDSCO directed state drug controllers to identify and act against unapproved manufacturers, marketers, distributors and retailers of Enclomiphene products, including suspending or cancelling manufacturing permissions and preventing further sales.
Why this matters
The CDSCO crackdown creates near-term regulatory and inventory risk for pharmacy, distribution and e-pharmacy businesses with Enclomiphene exposure, while favouring compliant, approved suppliers.
What to watch
- State drug controller inspection notices, seizure reports, licence suspensions or cancellation orders.
- CDSCO publication of named manufacturers, brands, batches, online platforms or product classifications affected.
- Marketplace and e-pharmacy delisting activity, prescription-policy changes and seller-account suspensions.
- Sharp changes in wholesale availability, distributor returns, pricing or substitution demand for fertility and hormonal therapies.
- Further CDSCO advisories covering unapproved fixed-dose combinations, endocrine medicines or products marketed for male fertility and testosterone-related indications.